(14) The mechanisms underlying this potential action might involve IGF-1-mediated suppression of muscle cell-specific enzymes referred to as E3 ubiquitin ligases, including atrogin-1 and muscle ring finger protein-1 (MuRF1)
Such changes could enable healthcare systems to strengthen early obesity prevention programs, diagnosis, and treatment, integrate pharmacological therapy into primary healthcare, and shift from managing long-term complications to more effective preventive approaches
Janvier S, Sutter ED, Wynendaele E, Spiegeleer BD, Vanhee C, Deconinck E
Standard Prior Authorization Requirements Across most commercial insurers, the prior authorization for weight loss medication requires the following documentation: Current BMI from a clinical measurement within the past 30 days Comorbidity documentation if BMI is between 27 and 29.9 (diagnosis codes, lab values, treatment records) Lifestyle modification history showing participation in diet and exercise programs for a minimum of three to six months (progress notes, referral records, dietitian visits) Previous medication trials if step therapy is required (prescription records, documented reasons for discontinuation or inadequate response) Letter of medical necessity from the prescribing provider explaining why the requested medication is clinically appropriate Tips for Successful Authorization Submit the authorization proactively before the patient's first fill, not reactively after a pharmacy rejection Include all supporting labs and clinical notes with the initial submission to avoid requests for additional information Use the insurer's preferred authorization form when available, as non-standard submissions are more likely to be delayed Track authorization expiration dates and resubmit renewals 30 days before expiration If denied, always file a formal appeal
The best candidates are patients who have just had a massive weight loss either due to a procedure or diet and exercise
